ClinicalTrials.gg
Drug

Luspatercept clinical trials

Also written ACE-536, Reblozyl and BMS-986346.

studies test it
50
open now
23
in phase 3
12
first study started
2011

How each study uses luspatercept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the luspatercept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 Nov 2019 · REBLOZYL · BLA 761136 (FDA, Drugs@FDA)
European Union
25 Jun 2020 · Reblozyl · EMEA/H/C/004444 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Luspatercept
44
Luspatercept-aamt
2
Luspatercept Injectable Product
2

Brand

Reblozyl
11

Development codes

ACE-536
23
BMS-986346
7
MK-6143
4

Studies by the year they started

50 studies that test it; most in 2026 (10)

Studies that test luspatercept, by start year
YearStudies
20111
20132
20142
20162
20171
20181
20194
20201
20213
20227
20237
20243
20256
202610

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
32
Phase 3
12
Phase 4
4
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 21 · Other 29

Celgene (10) · Bristol-Myers Squibb (5) · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (5) · Institute of Hematology & Blood Diseases Hospital, China (3) · Peking Union Medical College Hospital (2) · Nanfang Hospital, Southern Medical University (2) · M.D. Anderson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1)

Often tested with

Tested in the same studies.

Pacritinib (1) · Momelotinib (1) · Azacitidine (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine and cedazuridine drug combination (1) · CA-4948 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 1 in phase 3

Studies that test luspatercept, phase 3 first.

Studies

Open first, then newest update. How each study uses luspatercept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test luspatercept →

Given beside what is tested · 4 — luspatercept is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call luspatercept · ClinicalTrials.gg INT000734

  • MeSH (NLM) C000621232luspaterceptConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) AQK7UBA1LSLUSPATERCEPTConfirmed FDA, NLM, Wikidata
  • RxNorm 2262544Confirmed FDA, Wikidata
  • Wikidata Q30314143luspaterceptConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C104012LuspaterceptOne source FDA
  • DrugBank DB12281One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.